End of Study report

I General information	
EudraCT number	2017-003860-11
NL number	NL60690.029.017
Title: *11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET*	
Sponsor	VU University Medical Center
Participating sites	☐ singlecenter:
	☐ multicenter, national
Principal Investigator	Dr. D.G. van Vuurden

II Study status	
☐ Terminated as planned	End date of study:
☒ Early Termination	End date early termination: 01-06-2018
Reason for early termination: *Moving of the pediatric oncology department from the Amsterdam UMC, location VUmc to the Princess Maxima Center in Utrecht due to centralization of pediatric oncology care in the Netherlands. ^{11}C-Erlotinib has a short half-life, making it logistically impossible to be administered at any other hospital than at the Amsterdam UMC, VUmc.*	
How many participants were included at the time it was decided to terminate the study early? What are the consequences for these participants? *No participants were included in the study, therefore there were no consequences for participants.*	
What are the consequences of the early termination for the study results? *This study was never formally open for inclusion. No data was collected, we won't be able to answer the primary and secondary research questions of the study.*	

III Status inclusion	
How many participants are included in the study?	0
What is the total number of participants that needed to be included according to protocol?	5-15
What is the cause for not reaching the intended number of participants? *This study was never formally open for inclusion.*	

IV Report drafted by	
Name and function:	Prof. Dr. G.J.L. Kaspers, Head of Pediatric Oncology at VUmc
Date report	19-11-2023
Signature